 |
Studies Available at the ACTU We offer the following types of studies: Screening Study Cohort: This is a study for those interested in learning more about the studies offered at the AIDS Clinical Trials Unit. The study provides free lab tests; which include CD4 counts and HIV viral load and automatic access to clinical trials for HIV infected persons interested in research participation. Studies for people who have never taken medicines to treat HIV ACTG 5175: This study will be examining if a once a day regimen works as well as a twice a day anti-HIV medication regimen. Participants must have taken anti-HIV medications less than seven days, have a CD4 count of less than 300, and cannot have received an anti-HIV vaccine, investigational medications within 30 days of study entry. Some study medications are provided in this 156-week study. ACTG 5202: This 132-week study will examine the safety and effectiveness of four different once a day anti-HIV drug regimens. Participants must have never taken anti-HIV medications before, have a viral load of greater than 1,000 and cannot have received an anti-HIV vaccine, investigational medications, or chemotherapy within 30 days of study entry. All study medications are provided. AIN503 / ACTG 5217: This 96-week study will evaluate the safety and effectiveness of treating early HIV infection or not. Participants will either receive emtricitabine, tenofovir, and Kaletra for 36 weeks or no medications. Volunteers must have a diagnosis of HIV within 6 months of study entry, have had no prior anti-HIV treatment, and have a CD4 > 350 and viral load > 500. Study medications are provided. Studies for people who need a new HIV treatment Panacos PA103001 This study will use a new class of drug, called a maturation inhibitor. The study drug, Bevirimat, will compare antiretroviral activity of up to 5 different doses in anti-HIV medication experienced patients. Participants must have a CD4 >200 and a viral load of 2,000-250,000, resistance to at least one class of anti-HIV medications, and currently receiving a drug regimen of at least 3 anti-HIV drugs. The study requires 14-days of observed study medication therapy and 2 12-hour PK visits. Bevirimat is provided and there is compensation for each study visit. Studies to treat the complications of HIV ACTG 5229: This study will see if taking the experimental drug, NucleomaxX, a uridine supplement, will reverse the loss of fat in the face, arms, legs, or buttocks. NucleomaxX is used in Europe as a food supplement, but is not approved by the U. S. Food and Drug Adminstration. Participants must be receiving AZT or d4T for at least 12 weeks consecutive prior to study entry, viral load < 5,000 within 45 days of study entry, and no plans to alter medications during the study. This study is for 48-weeks. ACTG 5212 This study is for participants who have a viral load of less than 200 but continue to have a low CD4 cell count (less than 200). The study will use the drug, palifermin, to see if it is effective in increasing CD4 counts. Palifermin is currently approved in treating mouth sores in cancer patients, but has not been approved by the U. S. Food and Drug Administration for the treatment of HIV. Participants must be receiving their current anti-HIV regimen for at least 6 months and no plans to change their medication regimen and cannot have allergies to E-coli derived medications. The study requires 3 consecutive days of study drug through IV injection. Compensation for some study procedures during this 24-week trial. Studies for people who want to stop anti-HIV medications Observational Studies ACTG 5128: Participants of this study must be a current or past participant in an ACTG study and agree to have a one-time blood draw. Volunteers will consent to use the new DNA sample for unspecified genetic testing. Compensation is provided for the one time visit. ACTG 5001: To enroll in this study, participants must be currently in an ACTG parent study or within 8 weeks of their last visit of current study. This study will look at the data from the other ACTG studies to examine the long term effects of HIV and treatment(s) over several years. Volunteers can have any viral load or CD4 count to be eligible. Compensation is provided for each visit. For More Information: Please call (614) 293-8112 and ask for our screening nurse.
|
